KR20220152318A - 암의 치료 및/또는 예방을 위한 의약품 - Google Patents

암의 치료 및/또는 예방을 위한 의약품 Download PDF

Info

Publication number
KR20220152318A
KR20220152318A KR1020227035364A KR20227035364A KR20220152318A KR 20220152318 A KR20220152318 A KR 20220152318A KR 1020227035364 A KR1020227035364 A KR 1020227035364A KR 20227035364 A KR20227035364 A KR 20227035364A KR 20220152318 A KR20220152318 A KR 20220152318A
Authority
KR
South Korea
Prior art keywords
gln
ser
glu
pro
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227035364A
Other languages
English (en)
Korean (ko)
Inventor
후미요시 오카노
다이스케 아카자와
Original Assignee
도레이 카부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도레이 카부시키가이샤 filed Critical 도레이 카부시키가이샤
Publication of KR20220152318A publication Critical patent/KR20220152318A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227035364A 2020-03-12 2021-03-11 암의 치료 및/또는 예방을 위한 의약품 Pending KR20220152318A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020043021 2020-03-12
JPJP-P-2020-043021 2020-03-12
PCT/JP2021/009798 WO2021182573A1 (ja) 2020-03-12 2021-03-11 癌の治療及び／又は予防のための医薬品

Publications (1)

Publication Number Publication Date
KR20220152318A true KR20220152318A (ko) 2022-11-15

Family

ID=77671643

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227035364A Pending KR20220152318A (ko) 2020-03-12 2021-03-11 암의 치료 및/또는 예방을 위한 의약품

Country Status (7)

Country Link
US (1) US20230129035A1 (https=)
EP (1) EP4119156A4 (https=)
JP (2) JP7797875B2 (https=)
KR (1) KR20220152318A (https=)
BR (1) BR112022018157A2 (https=)
CA (1) CA3175137A1 (https=)
WO (1) WO2021182573A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101638490B1 (ko) * 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
WO2023008459A1 (ja) * 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
AU2022316644A1 (en) * 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN117677398A (zh) * 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
EP4578457A1 (en) * 2022-08-24 2025-07-02 Toray Industries, Inc. Pharmaceutical for treating and/or preventing cancer
KR20250052364A (ko) * 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
AU2023329564A1 (en) * 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2024190815A1 (https=) * 2023-03-14 2024-09-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016526A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の治療及び予防用医薬組成物
WO2011096535A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防のための医薬品

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US6677436B1 (en) 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
HUE025678T2 (en) 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
MX342291B (es) 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
KR101842893B1 (ko) * 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
PT2832366T (pt) 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
KR102155531B1 (ko) 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
JP7342701B2 (ja) * 2018-03-30 2023-09-12 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP7103097B2 (ja) 2018-09-13 2022-07-20 トヨタ自動車株式会社 燃料電池車両

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016526A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の治療及び予防用医薬組成物
WO2011096535A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防のための医薬品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Hansjochen Wilke et al., Lancet Oncology, 2014, 15(11), 1224-1235
Shigenori Kadowaki et al., The ESMO World Congress on Gastrointestinal Cancer 2019, Abstract#SO-001

Also Published As

Publication number Publication date
BR112022018157A2 (pt) 2022-10-25
JPWO2021182573A1 (https=) 2021-09-16
JP2025092589A (ja) 2025-06-19
US20230129035A1 (en) 2023-04-27
JP7797875B2 (ja) 2026-01-14
WO2021182573A1 (ja) 2021-09-16
EP4119156A4 (en) 2024-05-08
CA3175137A1 (en) 2021-09-16
EP4119156A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
JP7342701B2 (ja) 癌の治療及び／又は予防用医薬組成物
KR102005308B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
KR20220152318A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20240024803A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20220153621A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20220152309A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20220151684A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20220153615A (ko) 암의 치료 및/또는 예방을 위한 의약품
RU2781542C2 (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
KR102959404B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
KR20240024074A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20250052364A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20250052369A (ko) 암의 치료 및/또는 예방을 위한 의약품
WO2024135809A1 (ja) 癌の治療及び／又は予防のための医薬品
KR20250052368A (ko) 암의 치료 및/또는 예방을 위한 의약품

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902